JJJianliang Jin

Jianliang Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianliang Jin has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Rong Wang

    Department of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging and Disease, Nanjing Medical University

    17 shared publications
  • Jiawen Zhou

    Department of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging and Disease, Nanjing Medical University

    13 shared publications
  • Haiyun Chen

    Department of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and Informatics Nanjing Medical University Nanjing Jiangsu China

    10 shared publications
  • Chunfeng Xie

    The State Key Laboratory of Reproductive Medicine, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, China

    9 shared publications
  • Dengshun Miao

    The State Key Laboratory of Reproductive Medicine, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, China

    9 shared publications
  • Ao Chen

    Department of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging and Disease, Nanjing Medical University

    8 shared publications

Latest Publications

  • Regional Anatomy of the Abdominal Cavity and Its Clinical Application

    by Jianliang Jin, Hao Xu, Fengyuan Li, Xiaodong Yang

  • Open Access

    Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription

    by Xin Gu, Yingqiang Du, Jin'GE Zhang, Jiyu Li, Haiyun Chen, Yujie Lin, Yue Wang, Chunli Zhang, Shiyu Lin, Nannan Hao, et al.

    Background and Aims: Inflammageing represents both a critical pathophysiological hallmark and independent risk factor for myocardial infarction (MI), with age‐related increases observed in MI incidence and severity of post‐MI ventricular remodelling. Novel therapeutic strategies targeting inflammageing‐driven mechanisms are urgently required to attenuate adverse ventricular remodelling following MI. This investigation was designed to elucidate the impact of fibroblast‐specific p16INK4a on inflammageing‐associated ventricular remodelling after MI and to develop a targeted nanotherapy to mitigate this process.Methods and Results: We found that p16‐mediated inflammageing positively correlated with the severity of post‐infarction ventricular remodelling in patients. POSTN‐driven p16INK4a knockout improved cardiac function, and reduced ventricular remodelling, myocardial inflammation and NLRP3 signalling activation following MI through downregulating STAT3‐mediated NLRP3 inflammasome and upregulating glutathione metabolism pathway in fibroblasts. P16INK4a overexpression induced NLRP3 signalling activation through upregulating NLRP3 transcribed by STAT3 in fibroblasts. In terms of mechanisms, p16INK4a interacted with STAT3, which depended on the SH2 domain of STAT3; P16INK4a promoted the interaction of EZH2 and STAT3, increased the di‐methylation on K49 and phosphorylation on Y705 of STAT3 by EZH2, and promoted NLRP3 transcription through regulating histone modification in the NLRP3 promoter by interfering the formation of Bmi‐1‐EZH2 or Bmi‐1‐BCL6 complex in fibroblasts. Injection of p16INK4a‐accumulated ageing cardiac fibroblasts, or p16INK4a overexpression adenovirus aggravated profibrosis and proinflammation in MI area. However, a novel FH peptide ‘FHKHKSPALSPV’‐neutrophil membrane proteins (NMPs)‐artificial lipid (Li) membranes‐mesoporous silica nanoparticle (MSN) core (FNLM)‐nanocaged p16INK4a‐siRNA, as a newly constructed nanomaterial drug, could prevent post‐infarction ventricular remodelling through inhibiting NLRP3 transcription in targeted cardiac fibroblasts and ameliorating proinflammation and profibrosis.Conclusions: P16INK4a drives inflammageing‐mediated post‐MI ventricular remodeling by activating STAT3/NLRP3 signaling in fibroblasts. Targeting p16INK4a via FNLM‐siRNA nanotherapy represents a novel strategy to ameliorate adverse cardiac remodelling, offering translational potential for clinical intervention.Key points: Mechanistic Insight: P16INK4a activates NLRP3 transcription via STAT3‐EZH2 crosstalk, disrupting epigenetic complexes (Bmi‐1‐EZH2/BCL6) to exacerbate post‐MI remodelling. Therapeutic Innovation: A fibroblast‐targeted FNLM nanoparticle delivering p16INK4a‐siRNA effectively silences NLRP3, reducing post‐MI inflammageing. Translational Impact: This study identifies p16INK4a‐STAT3 as a druggable axis and proposes FNLM‐p16INK4a‐siRNA as a promising nanotherapy for clinical post‐MI care.


  • Open Access

    Thymic Bmi-1 hampers γδT17 generation and its derived RORγt-IL-17A signaling to delay cardiac aging

    by Qiuyi Wang, Yue Wang, Yujie Lin, Jiawen Zhou, Zhiyuan Mao, Xin Gu, Haiyun Chen, Jiyu Li, Ao Chen, Jin’gE Zhang, et al.

    New immunosenescence targets for preventing senescence-associated pathological cardiac hypertrophy (SA-PCH) need to be explored. In the present study, with physiologically aged human and mouse samples, the IL-17A level increased with physiological aging, heart failure (HF), and SA-PCH and was negatively correlated with thymic Bmi-1 expression. Bmi-1 f/f LckCre + mice and Bmi-1 f/f littermates were generated to determine whether Bmi-1 delayed T cell aging by maintaining thymic T cell development to prevent SA-PCH. As a result, Bmi-1 promoted thymic T cell development by upregulating Notch signaling and prevented DN1 T cells from differentiating into γδT17 cells by downregulating γδT17 cell differentiation signaling. Bmi-1 upregulated Notch signaling by inhibiting p53-mediated Ikzf1 transcription at the −1,863 to −1,849 Ikzf1 promoter region. Bmi-1–RING1B promoted RORγt ubiquitination and degradation by proteasome to inhibit the production of IL-17A in γδT17 cells. Bmi-1 also downregulated Rorc transcribed by c-Maf by trimethylating H3K27 at the −1,511 to −1,497 Rorc promoter region. Subsequently, the number of peripheral γδT17 cells infiltrating the heart tissues was reduced, while alleviating IL-17A-dependent cardiac aging, hypertrophy, dysfunction, senescence-associated secretory phenotype (SASP), and macrophage–myofibroblast transition, ultimately improving SA-PCH. The RORγt inhibitor SR1001 and IL-17A neutralizing antibody ixekizumab prevented thymic RORγt-IL-17A-dependent SA-PCH. Furthermore, RORγt bound to Bmi-1 through ARG237 and to RING1B through GLU235, which could be used as a therapeutic strategy for SA-PCH to construct binding peptides promoting Bmi-1–RING1B binding to RORγt and degrading RORγt for inhibiting γδT17 cell differentiation and IL-17A production. Thus, thymic Bmi-1 prevented IL-17A-dependent SA-PCH by decreasing γδT17 cell numbers.


  • Top Cited Papers

    Gut microbial-derived phenylacetylglutamine accelerates host cellular senescence

    by Hao Yang, Tongyao Wang, Chenglang Qian, Huijing Wang, Dong Yu, Meifang Shi, Mengwei Fu, Xueguang Liu, Miaomiao Pan, Xingyu Rong, et al.

    Gut microbiota plays a crucial role in the host health in the aging process. However, the mechanisms for how gut microbiota triggers cellular senescence and the consequent impact on human aging remain enigmatic. Here we show that phenylacetylglutamine (PAGln), a metabolite linked to gut microbiota, drives host cellular senescence. Our findings indicate that the gut microbiota alters with age, which leads to increased production of phenylacetic acid (PAA) and its downstream metabolite PAGln in older individuals. The PAGln-induced senescent phenotype was verified in both cellular models and mouse models. Further experiments revealed that PAGln induces mitochondrial dysfunction and DNA damage via adrenoreceptor (ADR)–AMP-activated protein kinase (AMPK) signaling. Blockade of ADRs as well as senolytics therapy impede PAGln-induced cellular senescence in vivo, implying potential anti-aging therapies. This combined evidence reveals that PAGln, a naturally occurring metabolite of human gut microbiota, mechanistically accelerates host cellular senescence.


  • Retraction
    Open Access

    Retraction Note: Anti-aging effect of transplanted amniotic membrane mesenchymal stem cells in a premature aging model of Bmi-1 deficiency

    by Chunfeng Xie, Jianliang Jin, Xianhui Lv, Jianguo Tao, Rong Wang, Dengshun Miao

  • Open Access

    Bmi‐1 Epigenetically Orchestrates Osteogenic and Adipogenic Differentiation of Bone Marrow Mesenchymal Stem Cells to Delay Bone Aging

    by Jingyu Zhao, Ao Chen, Rong Wang, Dong Qiu, Haiyun Chen, Jiyu Li, Jin'GE Zhang, Tianxiao Wang, Yue Wang, Yujie Lin, et al.

    With the increase in the aging population, senile osteoporosis (SOP) has become a major global public health concern. Here, it is found that Prx1 and Bmi‐1 co‐localized in trabecular bone, bone marrow cavity, endosteum, and periosteum. Prx1‐driven Bmi‐1 knockout in bone‐marrow mesenchymal stem cells (BMSCs) reduced bone mass and increased bone marrow adiposity by inhibiting osteoblastic bone formation, promoting osteoclastic bone resorption, downregulating the proliferation and osteogenic differentiation of BMSCs, and upregulating the adipogenic differentiation of BMSCs. However, Prx1‐driven Bmi‐1 overexpression showed a contrasting phenotype to Prx1‐driven Bmi‐1 knockout in BMSCs. Regarding mechanism, Bmi‐1‐RING1B bound to DNMT3A and promoted its ubiquitination and inhibited DNA methylation of Runx2 at the region from 45047012 to 45047313 bp, thus promoting the osteogenic differentiation of BMSCs. Moreover, Bmi‐1‐EZH2 repressed the transcription of Cebpa by promoting H3K27 trimethylation at the promoter region −1605 to −1596 bp, thus inhibiting the adipogenic differentiation of BMSCs. It is also found that Prx1‐driven Bmi‐1 overexpression rescued the SOP induced by Prx1‐driven Bmi‐1 knockout in BMSCs. Thus, Bmi‐1 functioned as a hub protein in the epigenetic regulation of BMSCs differentiation to delay bone aging. The Prx1‐driven Bmi‐1 overexpression in BMSCs can be used as an approach for the translational therapy of SOP.


  • Porous Gelatin Methacrylate Gel Engineered by Freeze-Ultraviolet Promotes Osteogenesis and Angiogenesis

    by Haoran Wang, Jianfeng Li, Ran Qin, Fanyi Guo, Ruyu Wang, Yifeng Bian, Hanbang Chen, Hua Yuan, Yongchu Pan, Jianliang Jin, et al.

    Alveolar bone defect reconstruction is a common challenge in stomatology. To address this, a thermosensitive/photosensitive gelatin methacrylate (GelMA) gel was developed based on various air solubilities and light-curing technologies. The gel was synthesized by using a freeze-ultraviolet (FUV) method to form a porous and quickly (within 15 min) solidifying modified network structure. Unlike other gel scaffolds limited by complex preparation procedures and residual products, this FUV-GelMA gel shows favorable manufacturing ability, promising biocompatibility, and adjustable macroporous structures. The results from a rat model suggested that this gel scaffold creates a conducive microenvironment for mandible reconstruction and vascularization. In vitro experiments further confirmed that the FUV-GelMA gel promotes osteogenic differentiation of human bone marrow mesenchymal stem cells and angiogenesis of human umbilical vein endothelial cells. Investigation of the underlying mechanism focused on the p38 mitogen-activated protein kinase (MAPK) pathway. We found that SB203580, a specific inhibitor of p38 MAPK, abolished the therapeutic effects of the FUV-GelMA gel on osteogenesis and angiogenesis, both in vitro and in vivo. These findings introduced a novel approach for scaffold-based tissue regeneration in future clinical applications.


  • Open Access

    Author Correction: TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency

    by Haiyun Chen, Hongjie Chen, Jialong Liang, Xin Gu, Jiawen Zhou, Chunfeng Xie, Xianhui Lv, Rong Wang, Qing Li, Zhiyuan Mao, et al.


  • An Injectable Black Phosphorus Hydrogel for Rapid Tooth Extraction Socket Healing

    by Fanyi Guo, Jianfeng Li, Ziyu Chen, Tianxiao Wang, Ruyu Wang, Tianyao Wang, Yifeng Bian, Yifei Du, Hua Yuan, Yongchu Pan, et al.

    The excess production of reactive oxygen species (ROS) will delay tooth extraction socket (TES) healing. In this study, we developed an injectable thermosensitive hydrogel (NBP@BP@CS) used to treat TES healing. The hydrogel formulation incorporated black phosphorus (BP) nanoflakes, recognized for their accelerated alveolar bone regeneration and ROS-scavenging properties, and dl-3-n-butylphthalide (NBP), a vasodilator aimed at enhancing angiogenesis. In vivo investigations strongly demonstrated that NBP@BP@CS improved TES healing due to antioxidation and promotion of alveolar bone regeneration by BP nanoflakes. The sustained release of NBP from the hydrogel promoted neovascularization and vascular remodeling. Our results demonstrated that the designed thermosensitive hydrogel provided great opportunity not only for ROS elimination but also for the promotion of osteogenesis and angiogenesis, reflecting the "three birds with one stone" concept, and has tremendous potential for rapid TES healing.


  • Open Access

    Inflammasome activation and metabolic remodelling in p16‐positive aging cells aggravates high‐fat diet‐induced lung fibrosis by inhibiting NEDD4L‐mediated K48‐polyubiquitin‐dependent degradation of SGK1

    by Xin Gu, Haoyu Meng, Chengyi Peng, Shiyu Lin, Baihong Li, Lin Zhao, Xue Yang, Guangyan Wang, Wenyuan Cai, Jiawen Zhou, et al.

    Background: Chronic changes caused by a high‐fat diet (HFD) may be associated with weakened lung function in obese patients. However, few studies have focused on the role of senescent cells in HFD‐induced pulmonary fibrosis. This study aimed to determine whether (i) obesity causes the accumulation of aging cells in the lungs, (ii) p16 accumulation in aging epithelial cells or fibroblasts exacerbates long‐term HFD‐induced senescence‐associated pulmonary fibrosis (SAPF) and (iii) p16 deletion or clearance of aging cells ameliorates HFD‐induced SAPF through inactivation of the inflammasome and metabolic remodelling.Methods: Twelve‐month old male mice of p16INK4a (hereafter p16) knockout (p16−/−) and wild‐type (WT), ApoE knockout (ApoE−/−) and ApoE−/−p16−/− were fed a HFD to induce obesity, and the effects of treatment with the senolytic drug ABT263 or the SGK1 specific inhibitor EMD638683 on fibrosis, inflammaging, gene expression, integrin‐inflammasome signalling and metabolism were examined. A549 and IMR‐90 cells were transduced with p16‐overexpressing adenovirus, and treated with palmitic and oleic acids (P&O) to induce steatosis in vitro.Results: We found that long‐term HFD promoted the expression of p16 and the increase of senescent cells in the lung. P16 knockout or ABT263 treatment alleviated pulmonary fibrosis, the increase of senescent cells and senescence‐associated secretory phenotype (SASP) in HFD‐fed mice, as well as in P&O‐treated A549 and IMR‐90 cells. RNA sequencing and bioinformatics analyses revealed that p16 knockout inhibited activation of the integrin‐inflammasome pathway and cellular glycolysis. Mass spectrometry, co‐immunoprecipitation and GST pull‐down assays demonstrated that p16 bound to the N‐terminal of SGK1, thereby interfering with the interaction between the E3 ubiquitin ligase NEDD4L and SGK1, and subsequently inhibiting K48‐polyubiquitin‐dependent degradation of SGK1 mediated by the NEDD4L–Ubch5 complex. EMD638683 was found to alleviate HFD‐induced pulmonary fibrosis and activation of the integrin‐inflammasome pathway.Conclusion: P16 accumulation promoted activation of integrin– inflammasome pathway and cell glycolysis by binding to the N– terminal of SGK1, intefering with the interaction between the E3 ubiquitin ligase NEDD4L and SGK1, thereby inhibiting K48– polyubiquitin– dependent degradation of SGK1 mediated by the NEDD4L–Ubch5 complex. ABT263 or EMD638683 could be used as potential drugs to treat pulmonary fibrosis in obese patients.